Roger Santimaria

Title: Roger Santimaria: Innovator in Medical Biotechnology

Introduction

Roger Santimaria is a notable inventor based in Schlieren, Switzerland. He has made significant contributions to the field of medical biotechnology, particularly through his innovative work on IL-17A binding molecules. His research focuses on developing polypeptides that inhibit the activity of glycosylated IL-17A, which has important implications for medical applications.

Latest Patents

Roger Santimaria holds a patent for "IL-17A binding molecules and medical uses thereof." This invention relates to a polypeptide that comprises or consists of an amino acid sequence designed to inhibit the activity of glycosylated IL-17A. The polypeptide includes specific sequences and allows for variations in certain amino acid positions, providing a versatile approach to medical treatments. The patent also covers fusion constructs, compositions, and various medical uses involving the polypeptide.

Career Highlights

Roger Santimaria is associated with Covagen AG, a company that specializes in the development of innovative therapeutic solutions. His work at Covagen AG has positioned him as a key player in the biotechnology sector, contributing to advancements in medical treatments and therapies.

Collaborations

Roger collaborates with talented professionals in his field, including Michela Sillacci Melkko and Nadja Banziger. These collaborations enhance the research and development efforts at Covagen AG, fostering innovation and progress in medical biotechnology.

Conclusion

Roger Santimaria's contributions to the field of medical biotechnology through his patent on IL-17A binding molecules exemplify the impact of innovative research on healthcare. His work continues to pave the way for new medical treatments and therapies.